SEC Company Response from NOVARTIS AG (NVS, NVSEF) (CIK 0001114448) (NVS) — Apr 7, 2015
NOVARTIS AG (NVS, NVSEF) (CIK 0001114448)
Date: April 7, 2015 · CIK: 0001114448 · Accession: 0001104659-15-026222
AI Filing Summary & Sentiment
File numbers found in text: 001-15024
Letter
Re: Novartis AG Form 20-F for Fiscal Year Ended December 31, 2014 Filed January 27, 2015 File No. 001-15024
Dear Mr. Rosenberg:
We are in receipt of your letter addressed to Felix R. Ehrat, our Group General Counsel, dated March 30, 2015. As agreed in a recent telephone call between Barry Rosenfeld, of our affiliate Novartis Finance Corporation, and Mark Brunhofer, Senior Staff Accountant at SEC, we will respond to your letter on or before April 27, 2015.
Respectfully submitted,
Novartis AG
Show Raw Text
CORRESP 1 filename1.htm Novartis AG Postfach 4002 Basel Switzerland April 1, 2015 Mr. Jim B. Rosenberg Senior Assistant Chief Accountant US Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Re: Novartis AG Form 20-F for Fiscal Year Ended December 31, 2014 Filed January 27, 2015 File No. 001-15024 Dear Mr. Rosenberg: We are in receipt of your letter addressed to Felix R. Ehrat, our Group General Counsel, dated March 30, 2015. As agreed in a recent telephone call between Barry Rosenfeld, of our affiliate Novartis Finance Corporation, and Mark Brunhofer, Senior Staff Accountant at SEC, we will respond to your letter on or before April 27, 2015. Respectfully submitted, Novartis AG /s/ HARRY KIRSCH /s/ FELIX R. EHRAT Harry Kirsch Felix R. Ehrat Chief Financial Officer General Counsel Novartis Group Novartis Group